Pulmonx (LUNG) Competitors $1.69 +0.16 (+10.46%) Closing price 04:00 PM EasternExtended Trading$1.65 -0.04 (-2.37%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LUNG vs. BWAY, OM, STIM, SGHT, SI, NYXH, INGN, INFU, KRMD, and MGRMShould you be buying Pulmonx stock or one of its competitors? The main competitors of Pulmonx include Brainsway (BWAY), Outset Medical (OM), Neuronetics (STIM), Sight Sciences (SGHT), Shoulder Innovations (SI), Nyxoah (NYXH), Inogen (INGN), InfuSystem (INFU), KORU Medical Systems (KRMD), and Monogram Orthopaedics (MGRM). These companies are all part of the "medical equipment" industry. Pulmonx vs. Its Competitors Brainsway Outset Medical Neuronetics Sight Sciences Shoulder Innovations Nyxoah Inogen InfuSystem KORU Medical Systems Monogram Orthopaedics Pulmonx (NASDAQ:LUNG) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Does the media favor LUNG or BWAY? In the previous week, Brainsway had 20 more articles in the media than Pulmonx. MarketBeat recorded 20 mentions for Brainsway and 0 mentions for Pulmonx. Brainsway's average media sentiment score of 0.68 beat Pulmonx's score of 0.00 indicating that Brainsway is being referred to more favorably in the news media. Company Overall Sentiment Pulmonx Neutral Brainsway Positive Which has preferable valuation and earnings, LUNG or BWAY? Brainsway has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulmonx$83.79M0.82-$56.39M-$1.43-1.18Brainsway$46.08M6.23$2.92M$0.2658.46 Which has more volatility & risk, LUNG or BWAY? Pulmonx has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Do analysts rate LUNG or BWAY? Pulmonx currently has a consensus price target of $7.66, suggesting a potential upside of 353.51%. Brainsway has a consensus price target of $18.00, suggesting a potential upside of 18.42%. Given Pulmonx's higher probable upside, analysts plainly believe Pulmonx is more favorable than Brainsway.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmonx 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56Brainsway 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LUNG or BWAY more profitable? Brainsway has a net margin of 11.60% compared to Pulmonx's net margin of -62.88%. Brainsway's return on equity of 8.97% beat Pulmonx's return on equity.Company Net Margins Return on Equity Return on Assets Pulmonx-62.88% -69.76% -36.26% Brainsway 11.60%8.97%5.65% Do insiders and institutionals hold more shares of LUNG or BWAY? 91.0% of Pulmonx shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 6.8% of Pulmonx shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryBrainsway beats Pulmonx on 12 of the 16 factors compared between the two stocks. Get Pulmonx News Delivered to You Automatically Sign up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LUNG vs. The Competition Export to ExcelMetricPulmonxMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.87M$2.15B$5.82B$9.73BDividend YieldN/AN/A3.84%4.09%P/E Ratio-1.1838.6631.1525.96Price / Sales0.8213.84474.77122.97Price / CashN/A50.7737.1558.38Price / Book0.996.709.116.39Net Income-$56.39M-$63.67M$3.26B$265.56M7 Day Performance8.33%4.61%2.12%1.98%1 Month Performance-47.84%3.25%5.13%1.33%1 Year Performance-75.40%27.99%31.25%21.15% Pulmonx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LUNGPulmonx3.9608 of 5 stars$1.69+10.5%$7.66+353.5%-78.8%$68.87M$83.79M-1.18250High Trading VolumeBWAYBrainsway3.3228 of 5 stars$14.85+14.4%$18.00+21.2%+88.6%$245.33M$41.02M57.12120News CoverageShort Interest ↓High Trading VolumeOMOutset Medical1.5298 of 5 stars$13.67+2.9%$24.67+80.4%+32.1%$236.11M$113.69M-0.67520Analyst ForecastSTIMNeuronetics2.406 of 5 stars$3.54+6.0%$7.00+97.7%+240.5%$220.86M$74.89M-3.13180Gap UpSGHTSight Sciences1.5164 of 5 stars$4.19-0.2%$4.27+1.8%-35.3%$219.94M$79.87M-4.36210Analyst ForecastSIShoulder InnovationsN/A$14.34+1.8%N/AN/A$214.57MN/A-0.4861NYXHNyxoah2.2861 of 5 stars$6.57+5.6%$15.00+128.3%-24.9%$211.86M$4.89M-3.08110Earnings ReportShort Interest ↑Analyst RevisionGap UpINGNInogen4.3598 of 5 stars$7.55+1.2%$11.00+45.7%-39.6%$201.72M$335.70M-7.121,030Positive NewsINFUInfuSystem3.149 of 5 stars$9.53-1.0%$12.50+31.2%N/A$194.66M$139.89M158.86410KRMDKORU Medical Systems1.2124 of 5 stars$4.21+1.0%$4.63+9.9%+86.0%$192.80M$33.65M-46.7880MGRMMonogram Orthopaedics1.63 of 5 stars$5.32-0.2%$5.40+1.5%+64.5%$190.22M$370K-10.6428Trending NewsEarnings ReportShort Interest ↓Analyst Revision Related Companies and Tools Related Companies Brainsway Competitors Outset Medical Competitors Neuronetics Competitors Sight Sciences Competitors Shoulder Innovations Competitors Nyxoah Competitors Inogen Competitors InfuSystem Competitors KORU Medical Systems Competitors Monogram Orthopaedics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LUNG) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle, Microsoft, IBM… every major AI player will be forced to secure massive amounts of this material just t...True Market Insiders | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access